BROOKS — Brooks Laboratories Income Statement
0.000.00%
Last trade - 00:00
- IN₹2.80bn
- IN₹2.84bn
- IN₹632.05m
2019 March 31st | 2020 March 31st | 2021 March 31st | R2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 550 | 697 | 772 | 912 | 632 |
Cost of Revenue | |||||
Gross Profit | 156 | 229 | 297 | 206 | 62 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 699 | 789 | 838 | 1,126 | 963 |
Operating Profit | -149 | -92.2 | -65.7 | -214 | -330 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -149 | -135 | -89.9 | -239 | -384 |
Provision for Income Taxes | |||||
Net Income After Taxes | -148 | -153 | -194 | -193 | -311 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -148 | -244 | -194 | -113 | -209 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -148 | -244 | -194 | -113 | -209 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.62 | -6.75 | -7.75 | -4.56 | -8.47 |